November 2019

RE: TIKOSYN (dofetilide) 125, 250 and 500 mcg capsules - Supply Shortage

Dear Health Care Provider,

In keeping with Pfizer’s continued commitment to notify Health Care Providers of the latest product information, we are providing the following update regarding TIKOSYN® (dofetilide). Due to the prescribing nature and patient monitoring requirements for TIKOSYN, it is important that Health Care Providers are informed of the impending supply shortage of all presentations of TIKOSYN (125, 250 and 500 mcg capsules).

This supply shortage is due to manufacturing delays and anticipated to begin per the schedule below:
- TIKOSYN – 125 mcg (0.125 mg) capsules; shortage begins July 2020
- TIKOSYN – 250 mcg (0.25 mg) capsules; shortage begins November 2019
- TIKOSYN – 500 mcg (0.5 mg) capsules; shortage begins end of December 2019
- Hospital Unit Dose Blister packs – TIKOSYN (125, 250, 500 mcg capsules); shortages begin June 2020
- Hospital Distributed 14-count bottles – TIKOSYN (125, 250, 500 mcg capsules); shortages begin end of January 2020

Although the duration of the supply shortage is unknown at this time, TIKOSYN is expected to be out of stock at least until the second half of 2021.

Healthcare providers should use their clinical judgment and expertise to determine appropriate treatment options for their patients. The most current prescribing information, BOXED WARNING, and medication guide for TIKOSYN is available at:

If you have medical questions concerning the product, or if you need to report an adverse event, including product defects, please call the appropriate contact center below.

<table>
<thead>
<tr>
<th>Contact</th>
<th>Contact Information</th>
<th>Areas of Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Medical Information</td>
<td>1-800-438-1985, Option 3 (9am to 5pm ET Monday through Friday)</td>
<td>Medical questions regarding the product</td>
</tr>
<tr>
<td>Pfizer Safety</td>
<td>1-800-438-1985, Option 1 (24 hours a day 7 days per week)</td>
<td>To report adverse events or product complaints</td>
</tr>
</tbody>
</table>

Sincerely,

Olga Tarasova, M.D.
US Medical Affairs
Pfizer Inc.

(c) 2019 Pfizer Inc. All rights reserved.